Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

POMALIDOMIDE

hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle

DRUG

Dexamethasone

40mg (if patient \<75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle

Trial Locations (20)

13273

Institut Paoli Calmette,, Marseille

14033

Chru Caen, Caen

21000

CHU DIJON, Hôpital d'Enfants, Dijon

31059

CHRU, Hôpital Purpan, Toulouse

33604

Hôpital Haut-Leveque, Pessac

35033

CHRU RENNES 2, Hôpital Pontchaillou, Rennes

35056

CHRU RENNES 1, Hôpital Sud, Rennes

37044

CHRU- Hôpital Bretonneau, Tours

38043

CHRU, Hôpital A.Michallon, Grenoble

44035

CHRU, Hôtel Dieu, Nantes

51092

Hôpital Robert Debré, CHU Reims, Reims

54511

CHRU, Hôpitaux de Brabois, Vandœuvre-lès-Nancy

59037

Chru Lille, Lille

69495

Centre Hospitalier Lyon Sud -1, Pierre-Bénite

Centre Hospitalier Lyon Sud -2, Pierre-Bénite

75475

Hôpital Saint-Louis, Paris

75571

CHU - Hôpital St Antoine,, Paris

80054

CHRU-Hôpital Sud Amiens, Amiens

85025

Centre hospitalier départemental La Roche sur Yon, La Roche-sur-Yon

86021

CHRU POITIERS-Hôpital Jean Bernard, Poitiers

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

University Hospital, Lille

OTHER